Julie Rose Strathman, in Falls City, NE - Psychologist

Julie Rose Strathman, is a Psychologist - School based in Falls City, Nebraska. Julie Rose Strathman is licensed to practice in Nebraska (license number 2015006325) and her current practice location is 1415 Morton St, Falls City, Nebraska. She can be reached at her office (for appointments etc.) via phone at (402) 245-2825.

NPI number for Julie Rose Strathman is 1275091704 and her current mailing address is 1415 Morton St, Falls City, Nebraska. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1275091704.

Contact Information

	Julie Rose Strathman,
	1415 Morton St, Falls City, NE 68355-2759
	(402) 245-2825
	(402) 245-2022

Healthcare Provider's Profile

Full Name	Julie Rose Strathman
Gender	Female
Speciality	Psychologist - School
Location	1415 Morton St, Falls City, Nebraska
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1275091704
Provider Enumeration Date: 03/04/2019
Last Update Date: 03/04/2019

Medical Identifiers

Medical identifiers for Julie Rose Strathman such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1275091704	NPI	-	NPPES
2015006325	Medicaid	NE

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
103TS0200X	Psychologist - School	2015006325 (Nebraska)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Julie Rose Strathman is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Julie Rose Strathman, 1415 Morton St, Falls City, NE 68355-2759 Ph: (402) 245-2825	Julie Rose Strathman, 1415 Morton St, Falls City, NE 68355-2759 Ph: (402) 245-2825

News Archive

Orexigen Therapeutics first-quarter net loss decreases to $14.1 million

Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced financial results for the first quarter of 2010. For the quarter ended March 31, 2010, Orexigen reported a net loss of $14.1 million, or $0.30 per share attributable to common stockholders, as compared to a net loss of $19.3 million, or $0.56 per share attributable to common stockholders, for the first quarter of 2009.

Stress testing with MPI may not be needed for bariatric surgery candidates

A new study by researchers from Rhode Island Hospital has found that stress testing with myocardial perfusion imaging as part of a pre-operative workup for bariatric surgery candidates may be unnecessary.

Mayo research provides evidence supporting benefit of ablation for heart failure patients with AFib

Only 1 in 13 everyday patients could have participated in a pivotal international clinical trial looking at the use of catheter ablation to treat atrial fibrillation among people with heart failure.

Applications accepted for September 2010 CMPP examination

Applications are now being accepted for the September 2010 Certified Medical Publication Professional examination. Qualified candidates can take the three-hour exam during the September 1-30, 2010 testing window at approved locations around the globe.

Powerful clot-busting drugs reserved for selected patients with deep vein thrombosis

Not all patients with blood clots in their legs – a condition known as deep vein thrombosis – need to receive powerful but risky clot-busting drugs, according to results of a large-scale, multicenter clinical trial.

Julie Rose Strathman, - Psychologist in Falls City, NE